Diabetes Mellitus Clinical Trial
Official title:
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: - Assess the efficacy of foselutoclax compared to aflibercept - Assess the safety and tolerability of foselutoclax
Status | Recruiting |
Enrollment | 50 |
Est. completion date | June 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients aged =18 years. - Patients with nonproliferative DR and DME - Center-involved DME with Central Subfield Thickness (CST) =325-900 µm - BCVA in the SE (most affected) of 70 to 30 ETDRS letters (equivalent to 20/40 to 20/250 on the Snellen chart) Exclusion Criteria: - Concurrent disease in the study eye (SE) or structural damage, other than DME, that could compromise BCVA, prevent BCVA improvement, require medical or surgical intervention during the study period, confound interpretation of the results, or interfere with assessment of toxicity or Color Fundus Photography (CFP) in the SE. - Significant media opacities, including cataract, or posterior capsule opacification, which might interfere with VA, assessment of toxicity, or fundus imaging in either eye. - Any medical condition that is uncontrolled and may prevent participation in this study, as determined by the Investigator or disqualify individuals from enrollment. |
Country | Name | City | State |
---|---|---|---|
United States | Retina Research Institution of Texas | Abilene | Texas |
United States | California Retina Consultants | Bakersfield | California |
United States | Retina-Vitreous Associates Medical Group | Beverly Hills | California |
United States | Envision Ocular, LLC | Bloomfield | New Jersey |
United States | Midwest Eye | Carmel | Indiana |
United States | Rand Eye Institute | Deerfield Beach | Florida |
United States | Erie Retina Research, LLC | Erie | Pennsylvania |
United States | Retina Consultants of Carolina | Greenville | South Carolina |
United States | Cumberland Valley Retina Consultants | Hagerstown | Maryland |
United States | Salehi Retina Institute Inc. | Huntington Beach | California |
United States | University Retina and Macula Associates | Lemont | Illinois |
United States | Advanced Vision Research Institute | Longmont | Colorado |
United States | Florida Eye Associates | Melbourne | Florida |
United States | Vision Research Solutions, PLLC | Philadelphia | Pennsylvania |
United States | EyeHealth Northwest | Portland | Oregon |
United States | Sierra Eye Associates | Reno | Nevada |
United States | Austin Retina Associates | Round Rock | Texas |
United States | Retina Vitreous Associates of Florida | Saint Petersburg | Florida |
United States | Deep Blue Retina Clinical Research, PLLC | Southaven | Mississippi |
United States | Retina Center of Texas | Southlake | Texas |
United States | Bay Area Retina Associates | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
Unity Biotechnology, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean change from baseline in BCVA by ETDRS letter | Mean change from baseline in Best-Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter | 24 weeks | |
Secondary | Assess other efficacy outcome - Changes in BCVA | Changes in BCVA (ETDRS letters) from baseline to each visit through Week 36 | 24 and 36 weeks | |
Secondary | Assess other efficacy outcome - Changes in CST | Change in Central Subfield Thickness (CST) as measured in microns from baseline to each visit through Week 36 | 24 and 36 weeks | |
Secondary | Assess other efficacy outcome - ETDRS gains | Proportion of participants gaining =15, =10, =5, or =0 ETDRS letters in BCVA from baseline in the Study Eye (SE) to Week 36 | 24 and 36 weeks | |
Secondary | Assess other efficacy outcome - Rescue metrics | Proportion of participants who do not require rescue | 24 and 36 weeks | |
Secondary | Assess safety outcome - TEAE | Percentage of participants with at least one treatment-emergent ocular adverse event (AE) in the SE or Fellow Eye (FE) | 24 and 36 weeks | |
Secondary | Assess other efficacy outcome - Changes in BCVA | Changes in BCVA from baseline to last observation at or prior to Week 36 | 24 and 36 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |